Samsung Biologics

From Wikipedia, the free encyclopedia
Samsung Biologics Co., Ltd.
Company typePublic
KRX: 207940
IndustryBiopharmaceuticals
Founded2011; 13 years ago (2011)
Headquarters
Songdo, Incheon
,
South Korea
Area served
Worldwide
Key people
John Rim, President and CEO[1]
Owners
SubsidiariesSamsung Bioepis
Korean name
Hangul
Revised RomanizationSamseong Baiorojikseu
McCune–ReischauerSamsŏng Paiorojiksŭ
Websitewww.samsungbiologics.com

Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.

The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly and AstraZeneca.[2][3][4] Samsung Biologics also partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax,[5] during the COVID-19 pandemic.[6]

History[edit]

Founded in 2011,[7] Samsung Biologics built four manufacturing plants with a capacity of more than 600,000 liters, from 2011 to 2023, making it the world's largest contract-based manufacturer in the biopharmaceutical sector at a single site as of 2018.[8][9][10] Since 2020, Samsung Biologics has expanded to the United States, operating in New Jersey[11] and San Francisco.[12]

In 2012, it established Samsung Bioepis, a biosimilar medicine producer, with Biogen.[13] The company acquired full ownership of Samsung Bioepis in 2022 by purchasing all remaining shares from Biogen for $2.3 billion.[14]

In November 2019, Samsung Biologics became the first contract manufacturing organization to obtain ISO 27001 certification[15] and the first in the Korean biopharma industry to obtain an ISO 22301 certification in May 2020.[16] In 2020, Samsung Biologics introduced S-CHOice, a cell line expression technology, and S-Cellerate to shorten the period for developing drugs the next year.[17][18] The company also obtained ISO 45001, 50001, 14001, 9001 in May 2021 and ISO 37001, 27001, 27017 in 2022.[19] Also in 2022, Samsung Biologics launched S-DUAL, a bispecific antibody platform, and its DEVELOPICK platform, a service that selects candidate materials for new drugs.[20]

Samsung Biologics published its first annual sustainability report in June 2021. The company also joined the Frontier 1.5D initiative, which worked to limit the temperature rise within 1.5 degrees from pre-industrial times.[21] It was added to the Dow Jones Sustainability World Index later that year.[22] In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal work $411 million.[4] A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.[23]

References[edit]

  1. ^ Samsung Biologics Names John Rim as President and CEO
  2. ^ "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma.
  3. ^ "Samsung Biologics to manufacture AstraZeneca's Evusheld". The Korea Herald.
  4. ^ a b biopharma-reporter.com (2023-06-12). "Samsung Biologics inks biosimilar manufacturing deal with Pfizer". biopharma-reporter.com. Retrieved 2023-06-14.
  5. ^ "Moderna taps Samsung for fill-finish duties on 'hundreds of millions' of COVID-19 vaccine doses". Fierce Pharma.
  6. ^ "Samsung Biologics, GreenLight to produce COVID vaccine for Africa". The Korea Herald.
  7. ^ "Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
  8. ^ "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.
  9. ^ "Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
  10. ^ Manalac, Tristan (5 July 2023). "Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M". www.biospace.com.
  11. ^ Han-na, Park (6 June 2023). "[Bio USA] Samsung Biologics seeks giant leap with new plant, ADC tech". The Korea Herald.
  12. ^ Dan Stanton (16 June 2020). "Samsung Biologics selects San Francisco for first US facility". BioProcess International.
  13. ^ "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
  14. ^ Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.
  15. ^ "Samsung Biologics receives ISO certification". The Investor.
  16. ^ "Samsung Biologics wins int'l standard for biz continuity (ISO22301) for its third plant". Korea IT Times. 20 May 2020.
  17. ^ "Samsung Biologics launches S-CHOice cell line expression technology". The Korea Herald.
  18. ^ "Samsung Biologics launches CDO-accelerating platform S-Cellerate". Korea Biomedical Review.
  19. ^ "Samsung Biologics Obtains Four Global ISO Certifications". Contract Pharma.
  20. ^ Byung-yeul, Baek (7 October 2022). "Samsung Biologics launches bispecific antibody platform S-DUAL". Korea Times.
  21. ^ "New Samsung Bio plant to be 'partially' operational by end of 2022". Biopharma Reporter.
  22. ^ "Six Korean companies added to Dow Jones Sustainability World Index". The Korea Herald.
  23. ^ Yim, Hyunsu (4 July 2023). "Samsung Biologics unveils $897 million manufacturing deals for Pfizer". Reuters.

External links[edit]

  • Official website
  • Business data for Samsung Biologics:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Samsung_Biologics&oldid=1215310714"